Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Precision BioSciences, Inc. - Common Stock (NQ: DTIL )

4.500 UNCHANGED
Streaming Delayed Price Updated: 11:42 AM EST, Dec 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Precision BioSciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Report First Quarter Results on May 13, 2024
From Precision BioSciences, Inc.
Via Business Wire
Earnings Preview: Precision BioSciences
Via Benzinga
Precision BioSciences Announces Receipt of FDA Fast Track Designation for ECUR-506, iECURE’s Program for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency
From Precision BioSciences
Via Business Wire
Precision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024
From Precision BioSciences, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics
From Precision BioSciences, Inc.
Via Business Wire
DTIL Stock Earnings: Precision BioSciences Misses EPS, Misses Revenue for Q4 2023
DTIL stock results show that Precision BioSciences missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024
From Precision BioSciences, Inc.
Via Business Wire
Earnings Scheduled For March 27, 2024
Companies Reporting Before The Bell • Local Bounti (NYSE:LOCL) is projected to report quarterly loss at $2.41 per share on revenue of $8.70 million. 
Via Benzinga
Precision BioSciences Presents Preclinical Data Highlighting PBGENE-PMM as a Potential Therapy for Primary Mitochondrial Myopathy
From Precision BioSciences
Via Business Wire
Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency
From Precision BioSciences, Inc.
Via Business Wire
Why Zscaler Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Zscaler, Inc. (NASDAQ: ZS) shares fell sharply during Friday’s session following second-quarter results. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
SPX, Nasdaq Look To Continue Rally
Fresh off a fourth-straight monthly win on Wall Street, stocks are on the rise as the week winds down. 
Via Talk Markets
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Pre-market stock movers are worth checking on Friday as investors prepare for the last day of trading this week with all of the latest news! 
Via InvestorPlace
Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants
From Precision BioSciences, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Precision BioSciences Announces Proposed Public Offering of Common Stock and Warrants
From Precision BioSciences, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Precision BioSciences Announces Non-Exclusive Patent License Agreement with Caribou Biosciences
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Receives Pre-IND Feedback from US FDA for PBGENE-HBV as it Advances Towards Clinical Readiness
From Precision BioSciences
Via Business Wire
Precision BioSciences Promotes Naresh Tanna to Vice President of Investor Relations
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Receives Initial $7.5 Million Cash Payment and Equity Investment from TG Therapeutics for Azel-Cel in Treatment of Autoimmune Diseases
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Effect a Reverse Stock Split
From Precision BioSciences, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Is Multiple Sclerosis Focused TG Therapeutics Stock Trading Higher Today?
TG Therapeutics Inc (NASDAQ: TGTX) reported preliminary BRIUMVI U.S.  
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.